RECENT NEWS

VolitionRx’s Nu.Q vet cancer test is now available for pre-order to veterinarians at the point-of-care through Heska Corporation.

Tasso has announced that the TassoOne Plus, a new high-volume liquid blood collection device, has received CE mark certification and successfully fulfilled all of the performance, safety, and relevant product requirements under the new European Union Medical Device Regulation.

France-based start-up Previa Medical says it has raised €2.1 million in seed funding for SEPSI-SCORE, a specialist AI-based solution designed to improve the early detection of sepsis in healthcare facilities.

Beckman Coulter Life Sciences will have a full team of dedicated professionals and informative programming at the upcoming Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition, focussing on highlighting the benefits of automation to improve laboratory workflows.

IT professionals across health and social care are being invited to have their say over future plans for the IT systems that underpin the NHS.

Terumo Blood and Cell Technologies has announced US Food and Drug Administration (FDA) clearance and official launch of its IMUGARD WB Platelet Pooling Set, which supports extended shelf life of whole blood-derived platelets from five days to seven days.

Sophia Genetics is partnering with AstraZeneca to apply its multimodal technology and expertise to the biopharmaceutical company’s oncology portfolio.

Bio-Rad Laboratories has launched StarBright Blue-series and StarBright Yellow-series dyes to provide greater flexibility in conventional and full spectrum flow cytometry applications.

Roche has announced that it has expanded its collaboration with Janssen Biotech, to create companion diagnostics for targeted therapies, further strengthening research and innovation activities.

Homerton Hospital’s new Essential Services Laboratory was opened this week by Chief Executive Louise Ashley and Chair Sir John Gieve in a ribbon cutting ceremony.

Aiforia has received a contract award to provide artificial intelligence solutions for 25 NHS Trusts’ pathology departments in the UK to support the diagnosis of patients.

Ibex Medical Analytics has announced that Galen Prostate is now CE marked under the In Vitro Diagnostic Medical Devices Regulation (IVDR) for supporting pathologists in primary diagnosis of prostate biopsies. Galen Prostate is the first standalone AI-based cancer diagnostics product of its kind certified under the IVDR.

Aptamer Group, the developer of novel Optimer binders to enable innovation in the life sciences industry, has announced a new partnership with BaseCure Therapeutics for the development of Optimer-targeted gene therapies.

Point-of-care molecular diagnostics company Genedrive has announced that the UK’s National Institute for Health and Care Excellence (NICE) has preliminarily recommended that the Genedrive MT-RNR1 ID Kit can be used by the NHS following the evidence review as part of its Early Value Assessment (EVA) Programme.

Bio-Rad Laboratories has developed partnerships with leading innovative next-generation sequencing (NGS) instrument providers, gaining compatibility of the SEQuoia RNA Sequencing Library Preparation portfolio on new state-of-the-art sequencers, including the Singular Genomics G4 System.

Infonote Datasystems has developed an enhanced version of its Laboratory Information Management System (LIMS) designed specifically to deliver a range of extended features needed across the sector, including the ability to administer and control interactions beyond the immediate laboratory environment.

INTEGRA Biosciences has expanded its range of products to include eight-row and 12-column automation-friendly reagent reservoirs, offering a greater variety of reservoir dimensions to suit the increasing diverse applications of automated workstations.

The 16th International Conference on Molecular Epidemiology and Evolutionary Genetics of Infectious Diseases (MEEGID XVI) will take place on 14-17 November 2023 at the Hilton Dresden, Germany.

Neogap Therapeutics has received approval from the Swedish Medical Products Agency to start a clinical trial of its personalised cell therapy against colorectal cancer. The phase I/IIa trial is planned to be initiated during the first half of 2023.

The medical technology strategy will ensure patients can access safe, effective and innovative equipment and medical devices, and has been welcomed by BIVDA.